tbuckley/cabot-search huggingface dataset:
Soft tissue‐related complications and management around dental implants
Authors: Tali Chackartchi, Georgios E. Romanos, Anton Sculean
Journal: Periodontology 2000 (2019)

Abstract Implant installation for replacing missing teeth is a frequent treatment procedure with high long‐term survival and success rates. However, the success of implant therapy may be jeopardized by several complications related to mistakes in treatment planning, surgical procedure, management of hard and soft tissues, and infections. Increasing evidence suggests that the stability of the soft tissues surrounding osseointegrated dental implants may substantially influence long‐term clinical stability and esthetics. Therefore, when implant therapy is planned, the clinician must not only be able to perform the appropriate steps to maintain/create a stable soft tissue, but also needs to be aware of the potential sources for complications and possess the adequate knowledge for their appropriate management. The present paper provides an overview of the most important aspects related to the prevention and management of soft tissue‐related complications in conjunction with implant therapy. The current literature indicates that the presence of an adequate width of keratinized attached mucosa around dental implants may lead to better soft and hard tissue stability, less plaque accumulation, limited soft tissue recession, and lower incidence of peri‐implant mucositis. Proper implant positioning by carefully considering appropriate mesio‐distal and bucco‐lingual dimensions and implant angulation may prevent the loss of interdental soft tissues and development of soft tissue recessions. To optimize the width of keratinized attached mucosa, the appropriate soft tissue augmentation protocol should be selected for each particular indication. When the use of autogenous soft tissue grafts is planned, a thorough knowledge of the anatomical structures is mandatory in order to harvest soft tissue grafts of an appropriate quality and quantity and to avoid/minimize postoperative complications. Finally, the clinician needs to master the necessary steps in order to manage complications related to extensive bleeding and tissue necrosis that may occur in conjunction with soft tissue augmentation procedures.
<i>ICD</i>-<i>10</i> Coding of Type 2 Myocardial Infarction and Myocardial Injury as It Relates to US Centers for Medicare &amp; Medicaid Services Value-Based Payment Programs
Authors: Andrew E. Levy, Karen S. Ream, P. Michael Ho
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Editor's Note: <i>Listeria monocytogenes</i> Promotes Tumor Growth via Tumor Cell Toll-Like Receptor 2 Signaling
Authors: Bo Huang, Jie Zhao, Shiqian Shen, Hongxing Li, Kai-Li He, Guan-Xin Shen, Lloyd Mayer, Jay Unkeless, Dong Li, Ye Yuan, Gui-Mei Zhang, Huabao Xiong, Zuo-Hua Feng
Journal: Cancer Research (2019)

The editors were made aware of concerns by a reader regarding potential manipulation of data in [this article][1] ([1][2]). An internal review by the editors determined that the same β-actin Western blot image was used in Fig. 4A of this article and in Fig. 2C of an article published earlier by the
Preparations and Appliances
Authors: F SCHMELZ
Journal: BMJ (1952)

m an in the pars nerf,osa of the pituitary: the findings in an arfimal in which'nan internal'carotid artery was tied intra- durally showed that the feceptors lay in the prospncephalon.Dr. MARY PIcKPoRD dtescribed the chemical stimulation of the supraoptico-hypophysial system that follows injection of acetylcholine, nicotine, morphine, and femitin.Intra- carotid injection Qf adrenaline given prior to ani antidiuretic dose of acetylcholine regularly annulled the action of the -latter.Application of di-isopropylfluorophosphonafe ((D.F.P.) to the supraopti6 nuclei rendered injections of acetylcholine temporarily ineffective, though morphine still prevented-a high rate of urine flow.
Nuclear <i>S</i> -Nitrosylation Defines an Optimal Zone for Inducing Pluripotency
Authors: Palas K. Chanda, Shu Meng, Jieun Lee, Honchiu E. Leung, Kaifu Chen, John P. Cooke
Journal: Circulation (2019)

We found that cell-autonomous innate immune signaling causes global changes in the expression of epigenetic modifiers to facilitate nuclear reprogramming to pluripotency. A role of S-nitrosylation by inducible nitric oxide (NO) synthase, an important effector of innate immunity, has been previously described in the transdifferentiation of fibroblasts to endothelial cells. Accordingly, we hypothesized that S-nitrosylation might also have a role in nuclear reprogramming to pluripotency.We used murine embryonic fibroblasts containing a doxycycline-inducible cassette encoding the Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc), and genetic or pharmacological inhibition of inducible NO synthase together with the Tandem Mass Tag approach, chromatin immunoprecipitation-quantitative polymerase chain reaction, site-directed mutagenesis, and micrococcal nuclease assay to determine the role of S-nitrosylation during nuclear reprogramming to pluripotency.We show that an optimal zone of innate immune activation, as defined by maximal yield of induced pluripotent stem cells, is determined by the degree of activation of nuclear factor κ-light-chain-enhancer of activated B cells; NO generation; S-nitrosylation of nuclear proteins; and DNA accessibility as reflected by histone markings and increased mononucleosome generation in a micrococcal nuclease assay. Genetic or pharmacological inhibition of inducible NO synthase reduces DNA accessibility and suppresses induced pluripotent stem cell generation. The effect of NO on DNA accessibility is mediated in part by S-nitrosylation of nuclear proteins, including MTA3 (Metastasis Associated 1 Family Member 3), a subunit of NuRD (Nucleosome Remodeling Deacetylase) complex. S-Nitrosylation of MTA3 is associated with decreased NuRD activity. Overexpression of mutant MTA3, in which the 2 cysteine residues are replaced by alanine residues, impairs the generation of induced pluripotent stem cells.This is the first report showing that DNA accessibility and induced pluripotent stem cell yield depend on the extent of cell-autonomous innate immune activation and NO generation. This "Goldilocks zone" for inflammatory signaling and epigenetic plasticity may have broader implications for cell fate and phenotypic fluidity.
CXCL13, a B-cell chemoattractant factor, is expressed by malignant lymphocytes of Sezary Syndrome.
Authors: Maria Grazia Narducci, Maria Cristina Picchio, Cristina Lazzeri, Irene Angelucci, Enrico Scala, Daniele Remotti, Antonella Bresin, Giuseppe Lombardo, Marina Frontani, Diego Arcelli, Gianluca Ragone, Elisabetta Caprini, Giannandrea Baliva, Giandomenico Russo
Journal: Cancer Research (2007)

5123  Sezary Syndrome (SS) is a rare and aggressive form of Cutaneous T-Cell Lymphoma (CTCL) characterised by a distinct metastatic pattern mainly involving blood and skin. Ourexpression analyses performed by microarrays demostrated that many chemokines resulted up-regulated in this kind of lymphoma. Since these chemoattractant molecules play a critical role in cellular recruitment and homing to tissues and in the metastatic processes of several tumors we focused our attention on one of them named CXCL13, a lymphoid chemokine involved in B-cell compartmental homing within secondary lymphoid organs.  In this study we observe that both circulating and skin-infiltrating neoplastic lymphocytes of SS patients abundantly express CXCL13. Furthermore, by ELISA we found that this chemokine is detectable at very higher level on plasma of SS patients when compared to controls as well as in Mycosis Fungoides, a low grade variant of CTCL. These results has been confirmed also by immunohistochemistry analyses performed on skin and lymph-node biopsies of SS/MF patients.  Recently, a study described a novel positive regulatory mechanism of leukocyte migration that can works in a rich chemokine environment as inflammatory and neoplastic situations. In particular, this report demonstrated that CXCL13 enhances the chemotaxis of CCR7+ cells like B, T resting lymphocytes and dendritic cells in response to agonist CCL19/21 lymphoid tissue chemokines. (Paoletti S. et al, Blood, 2005, 105; 3405-12).  Since an high percentage of SS cells express CCR7 receptor (Narducci MG. et al, Blood, 107:1108-15) we assessed whether the CXCL13 was able to enhance the migration response also in lymphomonocytes of SS patients when added to CCL19/21. Results obtained by migration studies confirmed that this synergic mechanism is observable also on SS cells. Furthermore, we demonstrated that blocking the CCR7 receptor by a neutralizing antibody, the migration response induced by CCL19/21 in absence or presence of CXCL13 is abrogated. These results indicate that CCR7 is a necessary component for agonist-migration as well as synergism.  Immunohistochemical experiments performed to evaluate the CCL19/21 on skin and lymph-node biopsies of SS revealed, moreover, that these chemokines are expressed at comparable levels of controls.  All these findings indicate that CXCL13 over-expression could play a role in pathogenesis of SS enhancing the lymph-node and skin-homing of CCR7+neoplastic lymphocytes.  .
“You helped me keep my head above water”—experience of bereavement research after loss of a loved one in the ICU: insights from the ARREVE study
Authors: Alexandra Laurent, Jean Reignier, Amélie Le Gouge, Alice Cottereau, Mélanie Adda, Djillali Annane, Juliette Audibert, François Barbier, Patrick Bardou, Simon Bourcier, Jeremy Bourenne, Alexandre Boyer, François Brenas, Vincent Das, Arnaud Desachy, Jérôme Devaquet, Marc Feissel, Frédérique Ganster, Maïté Garrouste-Orgeas, Guillaume Grillet, Olivier Guisset, Rebecca Hamidfar-Roy, Anne-Claire Hyacinthe, Sebastien Jochmans, Mercé Jourdain, Alexandre Lautrette, Nicolas Lerolle, Olivier Lesieur, Fabien Lion, Philippe Mateu, Bruno Megarbane, Sybille Merceron, Emmanuelle Mercier, Jonathan Messika, Paul Morin-Longuet, Bénédicte Philippon-Jouve, Jean-Pierre Quenot, Anne Renault, Xavier Repesse, Jean-Philippe Rigaud, Ségolène Robin, Antoine Roquilly, Amélie Seguin, Didier Thevenin, Patrice Tirot, Isabelle Vinatier, Elie Azoulay, René Robert, Nancy Kentish-Barnes
Journal: Intensive Care Medicine (2019)
An Nfil3–Zeb2–Id2 pathway imposes Irf8 enhancer switching during cDC1 development
Authors: Prachi Bagadia, Xiao Huang, Tian-Tian Liu, Vivek Durai, Gary E. Grajales-Reyes, Maximilian Nitschké, Zora Modrusan, Jeffrey M. Granja, Ansuman T. Satpathy, Carlos G. Briseño, Marco Gargaro, Arifumi Iwata, Sunkyung Kim, Howard Y. Chang, Andrey S. Shaw, Theresa L. Murphy, Kenneth M. Murphy
Journal: Nature Immunology (2019)
Attention-Deficit/Hyperactivity Disorder, Hypomania, and Bipolar Disorder in Youth
Authors: Lauren V. Moran, Perihan Esra Guvenek-Cokol, Roy H. Perlis
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By Bmn 270, an AAV5-Based Gene Therapy Treatment for Hemophilia A
Authors: Brian Long, Krystal Sandza, Jennifer Holcomb, Juli Pherarolis, Lucy Crockett, Lillian Falese, Greg Hayes, Jeremy Arens, Charles A. O'Neill, Nancy Pryer, Carlos Fonck, Stephen Zoog, Christian Vettermann
Journal: Blood (2017)
Dry Scaly Patches and Nodules in a Middle-aged Man
Authors: Ruojun Wang, Yang Wang, Zhimiao Lin
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML).
Authors: Carlo Gambacorti-Passerini, Camille N. Abboud, Bjorn T. Gjertsen, Tim H. Brümmendorf, B. Douglas Smith, Pilar Giraldo-Castellano, Ulla Olsson-Strömberg, Susanne Saussele, Nathalie Bardy-Bouxin, Andrea Viqueira, Eric Leip, Jocelyn M Leone, Gianantonio Rosti, Justin M. Watts, Frank Giles, Andreas Hochhaus
Journal: Journal of Clinical Oncology (2019)

7012 Background: The tyrosine kinase inhibitor (TKI) BOS is approved for patients (pts) with Philadelphia chromosome (Ph)+ CML resistant/intolerant to prior therapy and newly diagnosed pts in CP. Methods: The ongoing phase 4 BYOND study is further evaluating efficacy and safety of BOS (starting dose 500 mg/d) for CML resistant/intolerant to prior TKIs. Primary endpoint (not powered) in Ph+ CP CML cohorts is cumulative confirmed major cytogenetic response (MCyR) by 1 y. Results: Of 163 pts who received BOS, 156 had Ph+ CP CML (46, 61 and 49 after 1, 2 and 3 prior TKIs, respectively). Across Ph+ CP CML cohorts, 51.9% of pts were male; median age was 61 y. As of 1 y after last enrolled pt (median follow-up 30.4 mo), 56.4% remained on BOS. Median BOS duration was 23.7 mo and median dose intensity after adjustment due to adverse events (AEs) 313 mg/d. Of 144 evaluable pts with a valid baseline assessment, cumulative confirmed MCyR by 1 y was 71.5% (95% confidence interval [CI] 63.4–78.7). Cumulative complete cytogenetic response rate anytime on treatment was 81.3% (95% CI 73.9–87.3). Cumulative molecular response (MR) rates were high across lines of therapy (Table). 10 deaths occurred (5 on treatment); 1-y overall survival rate was 98.0%. No pt progressed to accelerated/blast phase on treatment. 25.0% discontinued BOS due to AEs and 5.1% due to insufficient response. Most common treatment-emergent AEs (TEAEs) were diarrhea (87.8%) and nausea (41.0%). Grade 3/4 TEAEs in &gt; 10% of pts were diarrhea (16.7%) and increased alanine aminotransferase (ALT; 14.7%). The only TEAE leading to discontinuation in &gt; 5% of pts was increased ALT (5.1%). Conclusions: Most pretreated pts with Ph+ CP CML had MCyR by 1 y with BOS; a substantial proportion achieved or preserved major MR (MMR) and deep MR in all therapy lines. Results further support BOS use for Ph+ CP CML resistant/intolerant to prior TKIs. Clinical trial information: NCT02228382. [Table: see text]
Comparison of desmoplastic tumor stroma and normal stroma in breast cancer by MALDI-MS and histology directed protein profiling
Authors: Eduardo Dias, Erin Seeley, Darrell Ellsworth, Carlos Arteaga, Richard Caprioli, Melinda Sanders
Journal: Cancer Research (2008)

3948  Background: Complex interactions among proteins in both tumor epithelium and its surrounding stroma are likely involved in promoting breast cancer development and progression. The progressive alteration of mammary epithelium during neoplastic transformation is accompanied by peritumoral fibroblast proliferation and compositional changes in the extracellular matrix (ECM) collectively referred to as desmoplastic tumor stroma (DTS). This stroma is histologically and biochemically different from normal stroma; however, its role in facilitating malignant growth is incompletely characterized. This study compared mass spectrometry profiles of normal breast stroma and DTS to identify proteins dysregulated in the tumor microenvironment during neoplastic progression.  Methods: Human breast tumor specimens were obtained from 17 patients. Cases were selected which contained both areas of DTS and normal breast stroma in the frozen tissue samples. Two serial 12 µm sections were cut from each sample. One section was mounted onto a histology slide and stained with hematoxylin and eosin (H&E) and the adjacent section was thaw-mounted directly onto a gold-coated MALDI target plate. The H&E staining allowed the histological characterization and was a guide for the histology directed acoustic robotic matrix deposition on the tissue sections. Individual matrix spots of 200 µm in diameter were deposited on the DTS in the immediate vicinity of tumor areas and also on the normal stroma surrounding normal lobular units. Profile spectra were acquired from the marked areas across the sections by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS). Statistical comparisons by Significance Analysis of Microarrays (SAM) using a minimum 2 fold-change and false discovery rate  2-fold) in the desmoplastic tumor stroma and one protein showed greater expression in the normal stroma.  Discussion: Recent findings underscore that the stromal-epithelial interface is a critical mediator of oncogenic potential and suggest that the effectiveness of breast cancer therapies directed against ER, EGFR or microvessels might ultimately depend on the properties of the surrounding DTS. The identification of intermediary proteins in these signaling pathways and other undiscovered pathways by the comparative study of protein expression in normal stroma and DTS may ultimately lead to the manipulation of these pathways for the prevention and treatment of breast cancer. Identification of the differentially expressed proteins is currently underway.
A novel in vitro model for experimental therapeutic and pharmacokinetic/pharmacodynamic studies of antineoplastic drugs.
Authors: Alan P. Brown, Tage Carlson, Cho-Ming Loi, Michael J. Graziano
Journal: Cancer Research (2004)

2127  Dosing, scheduling, and sequencing (DSS) of anticancer agents plays an important role in the effective treatment of patients. We sought to develop a novel in vitro system that would: i) allow for the exposure of cancer cells to drug concentration-time profiles as achieved in humans, ii) provide a mechanism to study the effects of DSS, and pharmacokinetics/pharmacodynamics (PK/PD) in vitro, iii) permit the evaluation of multiple doses/cycles of treatment, iv) and determine optimal strategies for delivering individual and combination regimens. ∼106 HL60 cells/mL × 15mL were exposed to 1-β-D-Arabinofuranosylcytosine (ara-C, IC50 34.7 nM) in vitro in a hollow-fiber model which simulates the plasma concentration-time profiles of ara-C in patients. The model system utilizes computer programmable peristaltic pumps to circulate media (RPMI 1640, 10% FCS) thru HL60 containing hollow fiber bioreactors. Drugs are dosed into the system to achieve desired ‘peak’ concentrations, and eliminated according to the appropriate human half-life and pharmacokinetic profile of the drug. Continuous infusion (CI) ara-C was administered over 7days at 1X, 5X, 15X, and 50X the IC50. The same total cycle doses were fractionated, and administered as a single bolus, and by an every 12-hour dosing schedule. Samples from the bioreactor are taken every 24hours, and endpoints include cell counts, viability, and DNA analysis by FACS for cell cycle parameters. Data were analyzed by fitting an Emax PK/PD model to the log change in viable cells from baseline for each dose level and growth control (WinNonlin 3.3). Over 7 days of treatment, the change from baseline in viable cell counts for the growth control, 1X, 5X, 15X, and 50X IC50 doses given as CI were +0.79, −0.12, –1.07, −1.74, and –2.35 logs, respectively. The Emax PK/PD model fit the experimental data excellently (r2 = 0.99), with an Emax (CV%), EC50 and Eo of −2.47 (7.6%) logs, 126.7 (27.7%) nM, and 0.71 (21.1%) logs, respectively. The in vitro model correctly confirmed that, at equivalent total doses, administration of ara-C by CI provides significantly more potent activity compared to bolus dosing. The model also demonstrated saturable intracellular metabolism of ara-C whereby further increases in dose failed to provide additional cell kill. The ability of this in vitro pharmacodynamic model to assess the response of cancer cells to different doses and schedules of antineoplastic agents may be useful in the design of optimal dosing regimens for clinical trials, but requires validation with other cell lines and classes of drugs. Additional studies to evaluate the optimal scheduling and sequencing of drug combinations are in progress.